Guidelines

in Lymphedema

Applied

Type

Addition

Confidence

95%

Created

Mar 26, 2026

Evidence

2 sources

Rationale

The 'Guidelines' section was previously sparse, containing only a single study citation. I integrated the major 2024 multi-society PAD guideline (ACC/AHA/SVS) to provide high-level clinical guidance. I also included a systematic review that evaluates the quality of international PAD guidelines to provide a global perspective on screening and diagnosis standards. The existing lymphedema study was preserved and contextualized within the section.

Evidence

Gornik HL, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024. PMID: 38743805.
Verified source
PubMedDOI
Uyagu OD, et al. Quality assessment and comparative analysis on the recommendations of current guidelines on screening and diagnosis of peripheral arterial disease: a systematic review. BMJ Open. 2022. PMID: 36104133.
Verified source
PubMedDOI

Content Changes

Clinical practice guidelines provide evidence-based frameworks for the management of vascular pathologies. For lower extremity peripheral artery disease (PAD), the 2024 American College of Cardiology (ACC)/American Heart Association (AHA)/Society for Vascular Surgery (SVS) guideline offers updated recommendations for screening, diagnosis, and longitudinal management [@svs2024]. A systematic review of global PAD guidelines has emphasized the need for high-quality, standardized approaches to screening and diagnosis, noting variations in current international recommendations [@uyagu2022].

In the management of lymphedema, specific pharmacological interventions have been evaluated:
Rockson SG, et al. Pilot study of ketoprofen in lymphedema. *JCI Insight*. 2018. PubMed. [@rockson2018]
Go to section in textbookDispute / Submit evidenceAll updates